论文部分内容阅读
雌激素(E)替代疗法可防止绝经后妇女生殖道萎缩及骨质疏松,且能减少心血管意外。但因长期服E不加孕酮(P)将增加宫内膜增殖和内膜癌的危险,又因E疗法周期地加入P常伴有撤退性出血,故使E疗法受到限制。近年来,由于使用周期性的合成E、P比起天然E、P具有潜在缺点,为此作者使用人体天然E_2(17βE_2)及P_4(4-孕烯3,20-二酮)为E替代疗法。观察其对缓解绝经后症状,消除子宫出血,保护子宫内膜的可接受性及完全性。 E_2P_4组:将微粒化E_20.35 mg与微粒化
Estrogen (E) replacement therapy prevents genital atrophy and osteoporosis in postmenopausal women and reduces cardiovascular accidents. However, long-term service E without progesterone (P) will increase the risk of endometrial hyperplasia and endometrial cancer, and because E cycles are often associated with the withdrawal of P bleeding, so make E therapy is limited. In recent years, due to the potential disadvantages of using periodic synthetic E, P compared to natural E, P, the authors used human replacement of native E 2 (17βE 2) and P 4 (4-pregnne 3,20-dione) . Observe its to ease postmenopausal symptoms, eliminate uterine bleeding, protect endometrial acceptability and completeness. E_2P_4 group: the micronized E_20.35 mg and micronized